Adamas Pharmaceuticals Inc (ADMS) Stock Price, Quote, News and Overview
NASDAQ:ADMS - Nasdaq - Common Stock
ADMS Quote, Performance and Key Statistics
8.22
+0.06 (+0.74%)
The current stock price of ADMS is 8.22 null. In the past month the price increased by 1.86%. In the past year, price increased by 84.72%.
ADMS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ADMS
Company Profile
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. The company is headquartered in Emeryville, California and currently employs 138 full-time employees. The company went IPO on 2014-04-10. The firm is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.
Company Info
Adamas Pharmaceuticals Inc
1900 Powell St Ste 1000
Emeryville CALIFORNIA 94608 US
CEO: Neil F. McFarlane
Employees: 138
Company Website: https://adamaspharma.com/
Phone: 15104503554.0
Adamas Pharmaceuticals Inc / ADMS FAQ
What is the stock price of Adamas Pharmaceuticals Inc today?
The current stock price of ADMS is 8.22 null. The price increased by 0.74% in the last trading session.
What is the ticker symbol for Adamas Pharmaceuticals Inc stock?
The exchange symbol of Adamas Pharmaceuticals Inc is ADMS and it is listed on the Nasdaq exchange.
On which exchange is ADMS stock listed?
ADMS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Adamas Pharmaceuticals Inc stock?
14 analysts have analysed ADMS and the average price target is 8.69 null. This implies a price increase of 5.72% is expected in the next year compared to the current price of 8.22. Check the Adamas Pharmaceuticals Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Adamas Pharmaceuticals Inc worth?
Adamas Pharmaceuticals Inc (ADMS) has a market capitalization of 374.98M null. This makes ADMS a Small Cap stock.
How many employees does Adamas Pharmaceuticals Inc have?
Adamas Pharmaceuticals Inc (ADMS) currently has 138 employees.
What are the support and resistance levels for Adamas Pharmaceuticals Inc (ADMS) stock?
Adamas Pharmaceuticals Inc (ADMS) has a support level at 8.17 and a resistance level at 8.23. Check the full technical report for a detailed analysis of ADMS support and resistance levels.
Is Adamas Pharmaceuticals Inc (ADMS) expected to grow?
The Revenue of Adamas Pharmaceuticals Inc (ADMS) is expected to grow by 26.58% in the next year. Check the estimates tab for more information on the ADMS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Adamas Pharmaceuticals Inc (ADMS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADMS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADMS, evaluating the profitability, health, valuation and growth aspects
- Adamas Pharmaceuticals Inc (ADMS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Adamas Pharmaceuticals Inc (ADMS) Sales and EPS estimates to see what analysts future expectations are.
- Adamas Pharmaceuticals Inc (ADMS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Adamas Pharmaceuticals Inc (ADMS) Insider and Institutional Ownership to learn about the owners and their transactions.
- Adamas Pharmaceuticals Inc (ADMS) Stock Chart to make your own analysis
- Adamas Pharmaceuticals Inc (ADMS) Latest news and press-releases to stay up to date.
Does Adamas Pharmaceuticals Inc (ADMS) stock pay dividends?
ADMS does not pay a dividend.
When does Adamas Pharmaceuticals Inc (ADMS) report earnings?
Adamas Pharmaceuticals Inc (ADMS) will report earnings on 2022-03-01, after the market close.
What is the Price/Earnings (PE) ratio of Adamas Pharmaceuticals Inc (ADMS)?
Adamas Pharmaceuticals Inc (ADMS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.02).
ADMS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ADMS. When comparing the yearly performance of all stocks, ADMS is one of the better performing stocks in the market, outperforming 97.7% of all stocks.
ADMS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ADMS. While ADMS seems to be doing ok healthwise, there are quite some concerns on its profitability.
ADMS Financial Highlights
Over the last trailing twelve months ADMS reported a non-GAAP Earnings per Share(EPS) of -2.02. The EPS increased by 46.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -71.1% | ||
| ROA | -43.55% | ||
| ROE | N/A | ||
| Debt/Equity | -5.76 |
ADMS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 71% to ADMS. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 48.66% and a revenue growth 26.58% for ADMS